Next Article in Journal
Safety of BRAF+MEK Inhibitor Combinations: Severe Adverse Event Evaluation
Previous Article in Journal
An Anti-PSMA Immunotoxin Reduces Mcl-1 and Bcl2A1 and Specifically Induces in Combination with the BAD-Like BH3 Mimetic ABT-737 Apoptosis in Prostate Cancer Cells
Open AccessReview

Exploiting Cancer’s Tactics to Make Cancer a Manageable Chronic Disease

Brain Tumor Research Laboratory, Department of Neurological Surgery, University of California, Irvine, CA 92617, USA
*
Author to whom correspondence should be addressed.
Cancers 2020, 12(6), 1649; https://doi.org/10.3390/cancers12061649
Received: 17 April 2020 / Revised: 17 June 2020 / Accepted: 19 June 2020 / Published: 22 June 2020
The history of modern oncology started around eighty years ago with the introduction of cytotoxic agents such as nitrogen mustard into the clinic, followed by multi-agent chemotherapy protocols. Early success in radiation therapy in Hodgkin lymphoma gave birth to the introduction of radiation therapy into different cancer treatment protocols. Along with better understanding of cancer biology, we developed drugs targeting cancer-related cellular and genetic aberrancies. Discovery of the crucial role of vasculature in maintenance, survival, and growth of a tumor opened the way to the development of anti-angiogenic agents. A better understanding of T-cell regulatory pathways advanced immunotherapy. Awareness of stem-like cancer cells and their role in cancer metastasis and local recurrence led to the development of drugs targeting them. At the same time, sequential and rapidly accelerating advances in imaging and surgical technology have markedly increased our ability to safely remove ≥90% of tumor cells. While we have advanced our ability to kill cells from multiple directions, we have still failed to stop most types of cancer from recurring. Here we analyze the tactics employed in cancer evolution; namely, chromosomal instability (CIN), intra-tumoral heterogeneity (ITH), and cancer-specific metabolism. These tactics govern the resistance to current cancer therapeutics. It is time to focus on maximally delaying the time to recurrence, with drugs that target these fundamental tactics of cancer evolution. Understanding the control of CIN and the optimal state of ITH as the most important tactics in cancer evolution could facilitate the development of improved cancer therapeutic strategies designed to transform cancer into a manageable chronic disease. View Full-Text
Keywords: evolution of cancer therapy; surgical advances in gliomas; cancer stem cell; cancer metabolism; chromosomal instability; intra-tumoral heterogeneity; dominant cancer evolution strategies; future cancer therapeutics evolution of cancer therapy; surgical advances in gliomas; cancer stem cell; cancer metabolism; chromosomal instability; intra-tumoral heterogeneity; dominant cancer evolution strategies; future cancer therapeutics
Show Figures

Figure 1

MDPI and ACS Style

Afrasiabi, K.; Linskey, M.E.; Zhou, Y.-H. Exploiting Cancer’s Tactics to Make Cancer a Manageable Chronic Disease. Cancers 2020, 12, 1649.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop